Innovation Pharmaceuticals Inc (IPIX)

[BonelessCat]

The trial was a proof of concept clinical trial after preclinical work indicated B might be effective against human IBDs. It was designed to be nothing more and nothing less. That it very effectively treated (clinical remission) 10 of 17 may not be “statistically significant” due to conceptual trial design, but it is quite remarkable. Likewise, that each cohort showed increased efficacy with increased exposure to Brilacidin adds to any reliability of results.

To conclude no one is interested flies in the face of 17 out of 17 responding to Brilacidin exposure and 10 of 17 had clinical remission. This in an area with no effective treatment.